新规格阿仑膦酸钠治疗老年骨质疏松症30例

Analysis of new specification alendronate in treating senile osteoporosis

目的观察新规格阿仑膦酸钠治疗老年骨质疏松的疗效及安全性。方法老年骨质疏松病人61例,随机分为2组,治疗组男性10例,女性20例,年龄(78±s 4)a,每周口服阿仑膦酸钠1片(70 mg),同时口服骨化三醇0.25μg·d^(-1);对照组男性11例,女性20例,年龄(77±6)a,仅服骨化三醇,疗程均为6 mo。观察2组骨骼疼痛情况及骨密度变化。结果治疗后,治疗组骨骼疼痛改善有效率87% (26/30),对照组65%(20/31),2组比较差异显著(P<0.05)。治疗组除华氏三角区外各部位骨密度均较治疗前上升,提高骨密度的有效率达73%(22/30),对照组为45%(14/31),2组间比较,差异有显著意义(P<0.05)。治疗前后2组三大常规,肝、肾功能等均无明显改变,无明显不良反应。结论新规格阿仑膦酸钠治疗老年骨质疏松安全、有效。

AIM for senile osteoporosis. To evaluate the clinical therapeutic effect and safety METHODS Sixty-one senile osteoporotic patients of new specification alendronate were randomly divided into two groups, 30 patients （M 10, F 20, age （78 ± s 4） a） in the treatment group and 31 patients （M 11, F 20, age （77 ± 6） a） in the control group. The patients in the treatment group were treated with alendronate 70 mg· wk^-1 and calcitriol 0.25 μg·d^-1, while the patients in the control group with calcitriol 0.25 μg·d^-1 only, both for 6 mo as a course. The changes of bone pain and bone mineral density （BMD） were closely observed. RESULTS After the therapy, pain alleviated efficacies of treatment group and control group were 87 % （26/ 30） and 65 % （20/31）, with significant difference （P 〈 0.05）. The BMD of the treatment group increased except that in Ward＇s angle area, to the average efficiency BMD of 73 % （22/30） , however, the control group increased the average efficient BMD of 45 % （14/31）, showing significant difference between the two groups （P 〈 0.05 ）. Biochemical levels of the three main routines, hepatic and renal functions of the two groups revealed no perceivable change. CONCLUSION Alendronate is effective and safe for treatment of senile osteoporosis.